ApconiX Welcomes Ken Page
ApconiX is delighted to welcome Ken (Kenneth) Page who is joining the Toxicology and DMPK Consultancy Team as a DMPK Specialist and will be working with Dr Richard Knight, Director and Co-founder of ApconiX.
Academic Career
Ken’s scientific career began straight after A-levels as a Laboratory Scientist in Drug Metabolism at May & Baker Ltd, London. Part of the training was to do a part-time Higher National Certificate (HNC) in applied biochemistry, which proved very useful when Ken attended the University of Warwick graduating with a BSc in Biochemistry. He then gained an MSc in Biopharmacy from the University of London.
Ken began his pharmaceutical career as a Section Manager in Drug metabolism and pharmacokinetics (DMPK)at Rhône Poulenc (now Sanofi) where he stayed for 15 years, until the site closed in 2000. Ken then moved north with his family to work for Astra-Zeneca at Alderley Park. At a time where DMPK was moving from being wholly development activity into being a split development and discovery activity, Ken joined the discovery DMPK team. Over the years, after several reorganisations, Ken Page supported projects in several disease areas including oncology, cardiovascular, asthma, inflammation and anti-bacterial agents. He left Astra-Zeneca in 2015 and joined RedX, as Principal Scientist.
In 2017 Ken moved on to Cyprotex, an ADME/Tox CRO located in Alderley Park, into a role that utilised his data management skills. Ken managed a team of software engineers working on the in-house LIMS, and a team of Project Managers, liaising between clients and the laboratory teams, ensuring that data was reported back to the client to time, quality and with the appropriate scientific interpretation.
Having spent much of his career at Alderley Park, Ken joked “I have spent 20 odd years here and I haven’t changed my parking space, it’s always been the same”.
Working at ApconiX
After 7 years at Cyprotex, Ken wanted to come back to his roots and start supporting DMPK and drug delivery projects. In the Project Team, Ken will be planning and managing DMPK studies for clients, and analysing DMPK studies results and offering advice on drug discovery and development strategy. Ken will also be helping ApconiX further develop and expand their in-house DMPK capability.
Dr Richard Knight, director and co-founder of ApconiX, commented “Toxicology and DMPK have always gone hand in hand, and so having someone of Ken’s knowledge and experience, especially in the discovery DMPK, is a great addition to our team. He has already provided valuable advice to our clients, as well as giving a lecture on DMPK principles to our staff. We are delighted to have him part of ApconiX.”
Interests outside of Work
Ken likes to walk and is looking forward to joining this year’s fundraising hike in Yorkshire. He also likes to read and watch cricket. Working part-time, Ken is keen to spend more time with family, especially his grandchildren.
